Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study

Castaman, G.; Rodeghiero, F.; Tosetto, A.; Cappelletti, A.; Baudo, F.; Eikenboom, J. C. J.; Federici, A. B.; Lethagen, Stefan; Linari, S.; Lusher, J.; Nishino, M.; Petrini, P.; Srivastava, A.; Ungerstedt, J. S.

Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study

Mark

Castaman, G. ; Rodeghiero, F. ; Tosetto, A. ; Cappelletti, A. ; Baudo, F. ; Eikenboom, J. C. J. ; Federici, A. B. ; Lethagen, Stefan ^LU ; Linari, S. and Lusher, J. , et al. (2006) In Journal of Thrombosis and Haemostasis 4(10). p.2164-2169

Abstract: Objectives: We undertook an international, multicenter study to describe the clinical picture and to estimate the bleeding risk in a group of obligatory carriers of type 3 von Willebrand disease (VWD). Patients and methods: Obligatory carriers (OC) of type 3 VWD were identified by the presence of offspring with type 3 VWD or by being an offspring of a type 3 patient. Normal controls were age- and sex-matched with the obligatory carriers. A physician-administered standardized questionnaire was used to evaluate hemorrhagic symptoms at presentation. A score system ranging from 0 (no symptom) to 3 (hospitalization, replacement therapy, blood transfusion) was used to quantitate bleeding manifestations. Odds ratios were computed for each... (More); Objectives: We undertook an international, multicenter study to describe the clinical picture and to estimate the bleeding risk in a group of obligatory carriers of type 3 von Willebrand disease (VWD). Patients and methods: Obligatory carriers (OC) of type 3 VWD were identified by the presence of offspring with type 3 VWD or by being an offspring of a type 3 patient. Normal controls were age- and sex-matched with the obligatory carriers. A physician-administered standardized questionnaire was used to evaluate hemorrhagic symptoms at presentation. A score system ranging from 0 (no symptom) to 3 (hospitalization, replacement therapy, blood transfusion) was used to quantitate bleeding manifestations. Odds ratios were computed for each symptom. Results: Ten centers participated to the study, enrolling a total of 35 type 3 VWD families, with 70 OC. A total of 215 normal controls and 42 OC for type 1 VWD were also included. About 40% of type 3 OC had at least one bleeding symptom compared to 23% of normal controls and 81.8% of type 1 OC (P < 0.0001 by chi-squared test), showing that type 3 OC clearly represent a distinct population from type 1 OC. The clinical situations associated with an increase of bleeding risk in type 3 OC were epistaxis [odds ratio 3.6; 90% confidence intervals (CI) 1.84-21.5], cutaneous bleeding (odds ratio 5.5; 90% CI 2.5-14.1) and postsurgical bleeding (odds ratio 16.3; 90% CI 4.5-59). The severity of bleeding score correlated with the degree of factor (F) VIII reduction in plasma. Conclusions: OC for type 3 VWD represent a distinctive population from type 1 OC. These patients, however, present with more frequent bleeding symptoms in comparison to normal controls, especially in case of significantly low FVIII. Desmopressin and/or tranexamic acid might be useful to prevent or treat bleeding in these cases. (Less)

Please use this url to cite or link to this publication: https://lup.lub.lu.se/record/686163

author

Castaman, G. ; Rodeghiero, F. ; Tosetto, A. ; Cappelletti, A. ; Baudo, F. ; Eikenboom, J. C. J. ; Federici, A. B. ; Lethagen, Stefan ^LU ; Linari, S. and Lusher, J. , et al. (More)

Castaman, G. ; Rodeghiero, F. ; Tosetto, A. ; Cappelletti, A. ; Baudo, F. ; Eikenboom, J. C. J. ; Federici, A. B. ; Lethagen, Stefan ^LU ; Linari, S. ; Lusher, J. ; Nishino, M. ; Petrini, P. ; Srivastava, A. and Ungerstedt, J. S. (Less)

organization

Department of Clinical Sciences, Malmö

publishing date

2006

type

Contribution to journal

publication status

published

subject

Cardiac and Cardiovascular Systems

keywords

carrier, inherited bleeding disorders, von Willebrand, von Willebrand factor, disease, bleeding score

in

Journal of Thrombosis and Haemostasis

volume

4

issue

10

pages

2164 - 2169

publisher

Wiley-Blackwell

external identifiers

wos:000240563100010
scopus:33748748642
pmid:16999850

ISSN

1538-7933

DOI

10.1111/j.1538-7836.2006.02070.x

language

English

LU publication?

yes

additional info

The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200)

id

677d7ab2-55d8-41c7-bc6a-e584955a9f85 (old id 686163)

date added to LUP

2016-04-01 11:50:26

date last changed

2022-01-26 19:03:29

@article{677d7ab2-55d8-41c7-bc6a-e584955a9f85,
  abstract     = {{Objectives: We undertook an international, multicenter study to describe the clinical picture and to estimate the bleeding risk in a group of obligatory carriers of type 3 von Willebrand disease (VWD). Patients and methods: Obligatory carriers (OC) of type 3 VWD were identified by the presence of offspring with type 3 VWD or by being an offspring of a type 3 patient. Normal controls were age- and sex-matched with the obligatory carriers. A physician-administered standardized questionnaire was used to evaluate hemorrhagic symptoms at presentation. A score system ranging from 0 (no symptom) to 3 (hospitalization, replacement therapy, blood transfusion) was used to quantitate bleeding manifestations. Odds ratios were computed for each symptom. Results: Ten centers participated to the study, enrolling a total of 35 type 3 VWD families, with 70 OC. A total of 215 normal controls and 42 OC for type 1 VWD were also included. About 40% of type 3 OC had at least one bleeding symptom compared to 23% of normal controls and 81.8% of type 1 OC (P &lt; 0.0001 by chi-squared test), showing that type 3 OC clearly represent a distinct population from type 1 OC. The clinical situations associated with an increase of bleeding risk in type 3 OC were epistaxis [odds ratio 3.6; 90% confidence intervals (CI) 1.84-21.5], cutaneous bleeding (odds ratio 5.5; 90% CI 2.5-14.1) and postsurgical bleeding (odds ratio 16.3; 90% CI 4.5-59). The severity of bleeding score correlated with the degree of factor (F) VIII reduction in plasma. Conclusions: OC for type 3 VWD represent a distinctive population from type 1 OC. These patients, however, present with more frequent bleeding symptoms in comparison to normal controls, especially in case of significantly low FVIII. Desmopressin and/or tranexamic acid might be useful to prevent or treat bleeding in these cases.}},
  author       = {{Castaman, G. and Rodeghiero, F. and Tosetto, A. and Cappelletti, A. and Baudo, F. and Eikenboom, J. C. J. and Federici, A. B. and Lethagen, Stefan and Linari, S. and Lusher, J. and Nishino, M. and Petrini, P. and Srivastava, A. and Ungerstedt, J. S.}},
  issn         = {{1538-7933}},
  keywords     = {{carrier; inherited bleeding disorders; von Willebrand; von Willebrand factor; disease; bleeding score}},
  language     = {{eng}},
  number       = {{10}},
  pages        = {{2164--2169}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Journal of Thrombosis and Haemostasis}},
  title        = {{Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study}},
  url          = {{http://dx.doi.org/10.1111/j.1538-7836.2006.02070.x}},
  doi          = {{10.1111/j.1538-7836.2006.02070.x}},
  volume       = {{4}},
  year         = {{2006}},
}

Lund University Publications

LUND UNIVERSITY LIBRARIES

Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study